Business News • PR NewsWire • Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

SHANGHAI, June 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient in Europe in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being...

View More : https://www.prnewswire.com:443/news-releases/asieris-announces-first-patient-treated-in-europe-in-apricity-the-multinati...

Releted News by prnewswire

Automotive Emissions Ceramics Market Expects 21.19 million units growth during 2021-2025 | Technavio

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Boliden invests in improved logistics for Harjavalta smelter

Castellum's half-year report January-June 2021 to be published on July 15, 2021 - invitation to teleconference